SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 10 – SEGMENT INFORMATION

The Company operates and manages its business as one reportable segment and operates as a clinical stage biopharmaceutical company. The Company’s current focus is on developing immunotherapy and cell therapies for the treatment of cancer. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

Significant segment expenses include research and development, officer compensation, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: 

	Year ended December 31,
	2024			2023
Revenue	$	-		$	-
Less:
Research and development		414			82
Officer compensation		119			-
Insurance		151			29
Stock-based compensation		218			913
Operating expenses		1,441			690
Other income (expenses)		(260	)		(98	)
NET LOSS	$	(2,603	)	$	(1,812	)